Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells

Journal of Experimental Therapeutics and Oncology

Volumn 6, Issue 1, 2006, Pages 23-29

  Rosetti, M ^a   Frasnelli, M ^b   Tesei, A ^a   Zoli, W ^a   Conti, M ^c  

^a ISTITUTO ONCOLOGICO ROMAGNOLO   (Italy)

^b ISTITUTO ZOOPROFILATTICO SPERIMENTALE DELLA LOMBARDIA E DELL EMILIA ROMAGNA   (Italy)

^c SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

Antidepressant drugs; Cancer; Cytotoxicity; Ion transporters; SSRIs

Indexed keywords

DOPAMINE TRANSPORTER; FLUOXETINE; NEUROTRANSMITTER RECEPTOR; NORADRENALIN TRANSPORTER; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE; ZIMELDINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER GROWTH; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG SPECIFICITY; HUMAN; HUMAN CELL; ION TRANSPORT; MEMBRANE TRANSPORT; NEUROTRANSMITTER RELEASE; NONHUMAN; NORADRENALIN RELEASE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZIMIDAZOLES; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CYCLOHEXANOLS; FIBROBLASTS; HUMANS; IONS; MICE; NECROSIS; NEOPLASMS; PAROXETINE; PROPIDIUM; SEROTONIN UPTAKE INHIBITORS;

EID: 33846042181     PISSN: 13594117     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Lastraioli E, Guasti L, Crociani O, Polvani S, Hofmann G, Witchel H, Bencini L, Calistri M, Messerini L, Scatizzi M, Moretti R, Wanke E, Olivotto M, Mugnai G, Arcangeli A. herg1 gene and HERG1 protein are overexpressed in colorectal cancers and regulate cell invasion of tumor cells. Cancer Res 64: 606-611, 2004.
2. Diss JK, Fraser SP, Djamgoz MB. Voltage-gated Na+ channels: multiplicity of expression, plasticity, functional implications and pathophysiological aspects. Eur Biophys J 33: 180-193, 2004.
3. Fraser SP, Diss JK, Chioni AM, Mycielska ME, Pan H, Yamaci RF, Pani F, Siwy Z, Krasowska M, Grzywna Z, Brackenbury WJ, Theodorou D, Koyuturk M, Kaya H, Battaloglu E, De Bella MT, Slade MJ, Tolhurst R, Palmieri C, Jiang J, Latchman DS, Coombes RC, Djamgoz MB. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin Cancer Res 11: 5381-5389, 2005.
4. Fraser SP, Grimes JA, Diss JK, Stewart D, Dolly JO, Djamgoz MB. Predominant expression of Kv1.3 voltage-gated K+ channel subunit in rat prostate cancer cell lines: electrophysiological, pharmacological and molecular characterisation. Pflugers Arch 446: 559-571, 2003.
5. Conti M. Targeting K+ channels for cancer therapy. J Exp Ther Oncol 4: 161-166, 2004.
6. Kunzelmann K. Ion channels and cancer. J Membr Biol 205: 159-173, 2005.
7. Schonherr R. Clinical relevance of ion channels for diagnosis and therapy of cancer. J Membr Biol 205: 175-184, 2005.
8. Gil-Ad I, Shtaif B, Levkovitz Y, Dayag M, Zeldich E, Weizman A. Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors. J Mol Neurosci 22: 189-198, 2004.
9. Xia Z, Depierre JW, Nassberger L. The tricyclic antidepressants clomipramine and citalopram induce apoptosis in cultured human lymphocytes. J Pharm Pharmacol 48: 115-116, 1996.
10. Xia Z, DePierre JW, Nassberger L. Modulation of apoptosis induced by tricyclic antidepressants in human peripheral lymphocytes. J Biochem Mol Toxicol 12: 115-123, 1998.
11. Abdul M, Logothetis CJ, Hoosein NM. Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154: 247-250, 1995.
12. Spanova A, Kovaru H, Lisa V, Lukasova E, Rittich B. Estimation of apoptosis in C6 glioma cells treated with antidepressants. Physiol Res 46: 161-164, 1997.
13. Serafeim A, Holder MJ, Grafton G, Chamba A, Drayson MT, Luong QT, Bunce CM, Gregory CD, Barnes NM, Gordon J. Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101: 3212-3219, 2003.
14. Peer D, Dekel Y, Melikhov D, Margalit R. Fluoxetine inhibits multidrug resistance extrusion pumps and enhances responses to chemotherapy in syngeneic and in human xenograft mouse tumor models. Cancer Res 64: 7562-7569, 2004.
15. Levkovitz, Y. Gil-Ad I, Zeldich E, Dayag M, Weizman A. Differential induction of apoptosis by antidepressants in glioma and neuroblasloma cell lines: evidence for p-c-Jun, cytochrome c, and caspase-3 involvement. J Mol Neurosci 27: 29-42, 2005.
16. Holliday SM, Benfield P. Venlafaxine. A review of its pharmacology and therapeutic potential in depression. Drugs 49: 280-294, 1995.
17. Zoli W, Ricotti L, Dal Susino M, Barzami F, Frassineti GL, Folli S, Tesei A, Bacci F, Amadori D. Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer. Br J Cancer 81: 609-615, 1999.
18. Skehan P, Storeng R, Seudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR. New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990.
19. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83: 757-766, 1991.
20. Reis M, Aberg-Wistedt A, Agren H, Hoglund P, Akerblad AC, Bengtsson F. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 19: 283-291, 2004.
21. Gilles M, Deuschle M, Kellner S, Shams M, Krumm B, Hartter S, Heuser I, Hiemke C. Paroxetine serum concentrations in depressed patients and response to treatment. Pharmacopsychiatry 38: 118-121, 2005.
22. Roscoe JA, Morrow GR, Hickok JT, Mustian KM, Griggs JJ, Matteson SE, Bushunow P, Qazi R, Smith B. Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy. Breast Cancer Res Treat 89: 243-249, 2005.
23. Miller A, Rabe-Jablonska J. [The effectiveness of antidepressants in the treatment of chronic non-cancer pain - a review]. Psychiatr Pol 39: 21-32, 2005.
24. Pae CU, Kim YJ, Won WY, Kim HJ, Lee S, Lee CU, Lee SJ, Kim DW, Lee C, Min WS, Kim CC, Paik IH, Serretti A. Paroxetine in the treatment of depressed patients with haematological malignancy: an open-label study. Hum Psychopharmacol 19: 25-29, 2004.
25. Golden RN. Making advances where it matters: improving outcomes in mood and anxiety disorders. CNS Spectr 9: 14-22, 2004.
26. Akechi T, Nakano T, Uchitomi Y. [Scientific background of psycho-oncology]. Seishin Shinkeigaku Zasshi 106: 764-771, 2004.
27. Preskorn SH, Lane RM. Sertraline 50 mg daily: the optimal dose in the treatment of depression. Int Clin Psychopharmacol 10: 129-141, 1995.
28. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA. Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 5: 322-329, 1993.
29. Barbey JT, Roose SP. SSR1 safety in overdose. J Clin Psychiatry 59 Suppl 15: 42-48, 1998.
30. Young TJ, Oliver GP, Pryde D, Perros M, Parkinson T. Antifungal activity of selective serotonin reuptake inhibitors attributed to non-specific cytotoxicity. J Antimicrob Chemother 51: 1045-1047, 2003.